ID   S6A19_HUMAN             Reviewed;         634 AA.
AC   Q695T7; A8K446;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 1.
DT   10-MAY-2017, entry version 117.
DE   RecName: Full=Sodium-dependent neutral amino acid transporter B(0)AT1;
DE   AltName: Full=Solute carrier family 6 member 19;
DE   AltName: Full=System B(0) neutral amino acid transporter AT1;
GN   Name=SLC6A19; Synonyms=B0AT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, VARIANT HND CYS-57,
RP   AND CHARACTERIZATION OF VARIANT HND CYS-57.
RX   PubMed=15286787; DOI=10.1038/ng1405;
RA   Kleta R., Romeo E., Ristic Z., Ohura T., Stuart C., Arcos-Burgos M.,
RA   Dave M.H., Wagner C.A., Camargo S.R.M., Inoue S., Matsuura N.,
RA   Helip-Wooley A., Bockenhauer D., Warth R., Bernardini I., Visser G.,
RA   Eggermann T., Lee P., Chairoungdua A., Jutabha P., Babu E.,
RA   Nilwarangkoon S., Anzai N., Kanai Y., Verrey F., Gahl W.A.,
RA   Koizumi A.;
RT   "Mutations in SLC6A19, encoding B(0)AT1, cause Hartnup disorder.";
RL   Nat. Genet. 36:999-1002(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, VARIANTS HND
RP   ASN-173; PRO-242 AND LYS-501, CHARACTERIZATION OF VARIANTS HND
RP   ASN-173; PRO-242 AND LYS-501, VARIANTS GLN-240 AND ILE-252, AND
RP   CHARACTERIZATION OF VARIANTS GLN-240 AND ILE-252.
RX   PubMed=15286788; DOI=10.1038/ng1406;
RA   Seow H.F., Broeer S., Broeer A., Bailey C.G., Potter S.J.,
RA   Cavanaugh J.A., Rasko J.E.J.;
RT   "Hartnup disorder is caused by mutations in the gene encoding the
RT   neutral amino acid transporter SLC6A19.";
RL   Nat. Genet. 36:1003-1007(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INVOLVEMENT IN HG AND IG.
RX   PubMed=19033659; DOI=10.1172/JCI36625;
RA   Broer S., Bailey C.G., Kowalczuk S., Ng C., Vanslambrouck J.M.,
RA   Rodgers H., Auray-Blais C., Cavanaugh J.A., Broer A., Rasko J.E.;
RT   "Iminoglycinuria and hyperglycinuria are discrete human phenotypes
RT   resulting from complex mutations in proline and glycine
RT   transporters.";
RL   J. Clin. Invest. 118:3881-3892(2008).
CC   -!- FUNCTION: Transporter that mediates resorption of neutral amino
CC       acids across the apical membrane of renal and intestinal
CC       epithelial cells. This uptake is sodium-dependent and chloride-
CC       independent. {ECO:0000269|PubMed:15286788}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Robust expression in kidney and small
CC       intestine, with minimal expression in pancreas. Also expressed in
CC       stomach, liver, duodenum, ileocecum, colon and prostate. Not
CC       detected in testis, whole brain, cerebellum, fetal liver, spleen,
CC       skeletal muscle, uterus, heart or lung.
CC       {ECO:0000269|PubMed:15286787, ECO:0000269|PubMed:15286788}.
CC   -!- DISEASE: Hartnup disorder (HND) [MIM:234500]: Autosomal recessive
CC       abnormality of renal and gastrointestinal neutral amino acid
CC       transport noted for its clinical variability. First described in
CC       1956, HND is characterized by increases in the urinary and
CC       intestinal excretion of neutral amino acids. Individuals with
CC       typical Hartnup aminoaciduria may be asymptomatic, some develop a
CC       photosensitive pellagra-like rash, attacks of cerebellar ataxia
CC       and other neurological or psychiatric features. Although the
CC       definition of HND was originally based on clinical and biochemical
CC       abnormalities, its marked clinical heterogeneity has led to it
CC       being known as a disorder with a consistent pathognomonic neutral
CC       hyperaminoaciduria. {ECO:0000269|PubMed:15286787,
CC       ECO:0000269|PubMed:15286788}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperglycinuria (HG) [MIM:138500]: A condition
CC       characterized by excess of glycine in the urine. In some cases it
CC       is associated with renal colic and renal oxalate stones.
CC       {ECO:0000269|PubMed:19033659}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry. SLC6A19
CC       deficiency combined with haploinsufficiency of SLC6A20 or
CC       partially inactivating mutations in SLC36A2, can be responsible
CC       for hyperglycinuria.
CC   -!- DISEASE: Iminoglycinuria (IG) [MIM:242600]: A disorder of renal
CC       tubular reabsorption of glycine and imino acids (proline and
CC       hydroxyproline), marked by excessive levels of all three
CC       substances in the urine. {ECO:0000269|PubMed:19033659}. Note=The
CC       disease may be caused by mutations affecting the gene represented
CC       in this entry. SLC6A19 deficiency combined with haploinsufficiency
CC       of SLC6A20 or partially inactivating mutations in SLC36A2, can be
CC       responsible for iminoglycinuria. Additional polymorphisms and
CC       mutations in SLC6A18 can contribute to the IG phenotype in some
CC       families.
CC   -!- SIMILARITY: Belongs to the sodium:neurotransmitter symporter (SNF)
CC       (TC 2.A.22) family. SLC6A19 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY596807; AAT42127.1; -; mRNA.
DR   EMBL; AY591756; AAT66171.1; -; mRNA.
DR   EMBL; AK290811; BAF83500.1; -; mRNA.
DR   EMBL; CH471102; EAX08175.1; -; Genomic_DNA.
DR   CCDS; CCDS34130.1; -.
DR   RefSeq; NP_001003841.1; NM_001003841.2.
DR   UniGene; Hs.481478; -.
DR   ProteinModelPortal; Q695T7; -.
DR   STRING; 9606.ENSP00000305302; -.
DR   GuidetoPHARMACOLOGY; 939; -.
DR   TCDB; 2.A.22.6.3; the neurotransmitter:sodium symporter (nss) family.
DR   iPTMnet; Q695T7; -.
DR   PhosphoSitePlus; Q695T7; -.
DR   BioMuta; SLC6A19; -.
DR   DMDM; 73919285; -.
DR   PaxDb; Q695T7; -.
DR   PeptideAtlas; Q695T7; -.
DR   PRIDE; Q695T7; -.
DR   DNASU; 340024; -.
DR   Ensembl; ENST00000304460; ENSP00000305302; ENSG00000174358.
DR   GeneID; 340024; -.
DR   KEGG; hsa:340024; -.
DR   UCSC; uc003jbw.5; human.
DR   CTD; 340024; -.
DR   DisGeNET; 340024; -.
DR   GeneCards; SLC6A19; -.
DR   HGNC; HGNC:27960; SLC6A19.
DR   HPA; HPA037415; -.
DR   HPA; HPA043207; -.
DR   MalaCards; SLC6A19; -.
DR   MIM; 138500; phenotype.
DR   MIM; 234500; phenotype.
DR   MIM; 242600; phenotype.
DR   MIM; 608893; gene.
DR   neXtProt; NX_Q695T7; -.
DR   OpenTargets; ENSG00000174358; -.
DR   Orphanet; 2116; Hartnup disease.
DR   Orphanet; 42062; Iminoglycinuria.
DR   PharmGKB; PA134968815; -.
DR   eggNOG; KOG3659; Eukaryota.
DR   eggNOG; COG0733; LUCA.
DR   GeneTree; ENSGT00760000119044; -.
DR   HOGENOM; HOG000116406; -.
DR   HOVERGEN; HBG071421; -.
DR   InParanoid; Q695T7; -.
DR   KO; K05334; -.
DR   OMA; GYVDECA; -.
DR   OrthoDB; EOG091G08PX; -.
DR   PhylomeDB; Q695T7; -.
DR   TreeFam; TF343812; -.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-HSA-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   ChiTaRS; SLC6A19; human.
DR   GeneWiki; SLC6A19; -.
DR   GenomeRNAi; 340024; -.
DR   PRO; PR:Q695T7; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000174358; -.
DR   CleanEx; HS_SLC6A19; -.
DR   ExpressionAtlas; Q695T7; baseline and differential.
DR   Genevisible; Q695T7; HS.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015171; F:amino acid transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0005328; F:neurotransmitter:sodium symporter activity; IEA:InterPro.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0006865; P:amino acid transport; TAS:Reactome.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   InterPro; IPR000175; Na/ntran_symport.
DR   InterPro; IPR002438; Na/ntran_symport_orphan.
DR   PANTHER; PTHR11616; PTHR11616; 1.
DR   Pfam; PF00209; SNF; 1.
DR   PRINTS; PR00176; NANEUSMPORT.
DR   PRINTS; PR01206; ORPHTRNSPORT.
DR   PROSITE; PS00610; NA_NEUROTRAN_SYMP_1; 1.
DR   PROSITE; PS50267; NA_NEUROTRAN_SYMP_3; 1.
PE   1: Evidence at protein level;
KW   Amino-acid transport; Complete proteome; Disease mutation;
KW   Glycoprotein; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Symport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1    634       Sodium-dependent neutral amino acid
FT                                transporter B(0)AT1.
FT                                /FTId=PRO_0000214809.
FT   TOPO_DOM      1     41       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     42     62       Helical; Name=1. {ECO:0000255}.
FT   TOPO_DOM     63     67       Extracellular. {ECO:0000255}.
FT   TRANSMEM     68     88       Helical; Name=2. {ECO:0000255}.
FT   TOPO_DOM     89    120       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    121    141       Helical; Name=3. {ECO:0000255}.
FT   TOPO_DOM    142    192       Extracellular. {ECO:0000255}.
FT   TRANSMEM    193    213       Helical; Name=4. {ECO:0000255}.
FT   TOPO_DOM    214    221       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    222    242       Helical; Name=5. {ECO:0000255}.
FT   TOPO_DOM    243    268       Extracellular. {ECO:0000255}.
FT   TRANSMEM    269    289       Helical; Name=6. {ECO:0000255}.
FT   TOPO_DOM    290    304       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    305    325       Helical; Name=7. {ECO:0000255}.
FT   TOPO_DOM    326    413       Extracellular. {ECO:0000255}.
FT   TRANSMEM    414    434       Helical; Name=8. {ECO:0000255}.
FT   TOPO_DOM    435    456       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    457    477       Helical; Name=9. {ECO:0000255}.
FT   TOPO_DOM    478    490       Extracellular. {ECO:0000255}.
FT   TRANSMEM    491    511       Helical; Name=10. {ECO:0000255}.
FT   TOPO_DOM    512    531       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    532    552       Helical; Name=11. {ECO:0000255}.
FT   TOPO_DOM    553    581       Extracellular. {ECO:0000255}.
FT   TRANSMEM    582    602       Helical; Name=12. {ECO:0000255}.
FT   TOPO_DOM    603    634       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES      17     17       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9D687}.
FT   MOD_RES     627    627       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9D687}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    182    182       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    368    368       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT      57     57       R -> C (in HND; abolishes transport
FT                                activity; dbSNP:rs762989809).
FT                                {ECO:0000269|PubMed:15286787}.
FT                                /FTId=VAR_023314.
FT   VARIANT     173    173       D -> N (in HND; population allele
FT                                frequency among Europeans is 0.007;
FT                                reduces transport activity by 50% but
FT                                does not completely inactivates the
FT                                transporter; dbSNP:rs121434346).
FT                                {ECO:0000269|PubMed:15286788}.
FT                                /FTId=VAR_023315.
FT   VARIANT     240    240       R -> Q (in dbSNP:rs758492838).
FT                                {ECO:0000269|PubMed:15286788}.
FT                                /FTId=VAR_023316.
FT   VARIANT     242    242       L -> P (in HND; completely abolishes the
FT                                transport activity; dbSNP:rs200745023).
FT                                {ECO:0000269|PubMed:15286788}.
FT                                /FTId=VAR_023317.
FT   VARIANT     252    252       V -> I (in dbSNP:rs7732589).
FT                                {ECO:0000269|PubMed:15286788}.
FT                                /FTId=VAR_023318.
FT   VARIANT     501    501       E -> K (in HND; completely abolishes the
FT                                transport activity).
FT                                {ECO:0000269|PubMed:15286788}.
FT                                /FTId=VAR_023319.
SQ   SEQUENCE   634 AA;  71110 MW;  B85EFB02F9D53BB9 CRC64;
     MVRLVLPNPG LDARIPSLAE LETIEQEEAS SRPKWDNKAQ YMLTCLGFCV GLGNVWRFPY
     LCQSHGGGAF MIPFLILLVL EGIPLLYLEF AIGQRLRRGS LGVWSSIHPA LKGLGLASML
     TSFMVGLYYN TIISWIMWYL FNSFQEPLPW SDCPLNENQT GYVDECARSS PVDYFWYRET
     LNISTSISDS GSIQWWMLLC LACAWSVLYM CTIRGIETTG KAVYITSTLP YVVLTIFLIR
     GLTLKGATNG IVFLFTPNVT ELAQPDTWLD AGAQVFFSFS LAFGGLISFS SYNSVHNNCE
     KDSVIVSIIN GFTSVYVAIV VYSVIGFRAT QRYDDCFSTN ILTLINGFDL PEGNVTQENF
     VDMQQRCNAS DPAAYAQLVF QTCDINAFLS EAVEGTGLAF IVFTEAITKM PLSPLWSVLF
     FIMLFCLGLS SMFGNMEGVV VPLQDLRVIP PKWPKEVLTG LICLGTFLIG FIFTLNSGQY
     WLSLLDSYAG SIPLLIIAFC EMFSVVYVYG VDRFNKDIEF MIGHKPNIFW QVTWRVVSPL
     LMLIIFLFFF VVEVSQELTY SIWDPGYEEF PKSQKISYPN WVYVVVVIVA GVPSLTIPGY
     AIYKLIRNHC QKPGDHQGLV STLSTASMNG DLKY
//
